Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 19.0 pts more than Nifty Microcap 250 and 19.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma reported its Q1 FY26 results, with standalone revenue from operations rising about 10% year-on-year to Rs 163.36 crore (from Rs 148.96 crore in Q1 FY25). Standalone net profit grew roughly 8% to Rs 21.05 crore, with basic EPS of Rs 2.00 versus Rs 1.85 a year ago. On a consolidated basis, revenue climbed to Rs 207.47 crore, while net profit jumped to Rs 44.36 crore from Rs 22.11 crore, more than doubling year-on-year. The company has deconsolidated its step-down subsidiary Greenlife Bliss Healthcare (sold 51% stake for USD 1.3 million) effective April 1, 2025, which impacts the consolidated comparability. Statutory auditors Kalyaniwalla & Mistry LLP issued an unmodified limited review report on both sets of results.
Results are largely in line-to-positive: consolidated earnings saw a sharp jump, though partly helped by the deconsolidation effect. Standalone performance shows steady single-digit growth, while finance costs have risen over fourfold year-on-year, which investors should watch. Overall, the clean audit report and EPS growth are supportive for shareholders.